Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2022
PHARMAC publishes agenda for November 2022 PTAC meeting
21 October 2022 - The agenda for the November 2022 PTAC meeting is now available. ...
Posted by Michael Wonder on 23 Oct 2022
New cancer medicines added to the PBS
22 October 2022 - Cancer medications and a treatment for a rare genetic disease have been added to Australia's PBS. ...
Posted by Michael Wonder on 22 Oct 2022
Labor fulfils vow to cut cost of scripts
21 October 2022 - Labor will list four new medicines on the PBS from November to offer Australians cheaper treatments ...
Posted by Michael Wonder on 21 Oct 2022
PBS minimum stockholding requirements
21 October 2022 - Amendments made by the National Health Amendment Act 2021 give effect to the commitments in the new ...
Posted by Michael Wonder on 20 Oct 2022
Consultation on the revised PBS post-market review framework
20 October 2022 - The Department of Health and Aged Care is inviting stakeholders to provide feedback on a revised ...
Posted by Michael Wonder on 20 Oct 2022
Department of Health tweaks the agenda for November 2022 PBAC meeting
19 October 2022 - Two minor changes made the day after the release of version 3. ...
Posted by Michael Wonder on 20 Oct 2022
New Zealand, it's time to put Fairness in Focus
20 October 2022 - Medicines New Zealand is today relaunching their digital public awareness platform Fairness in Focus. ...
Posted by Michael Wonder on 19 Oct 2022
Fostamatinib disodium hexahydrate for the treatment of patients with refractory chronic immune thrombocytopenia
19 October 2022 - NICE has published evidence-based recommendations on the use of fostamatinib disodium hexahydrate for the treatment of ...
Posted by Michael Wonder on 19 Oct 2022
Zanubrutinib for the treatment of patients with Waldenström’s macroglobulinaemia
19 October 2022 - NICE has published evidence-based recommendations on the use of zanubrutinib for the treatment of adults with ...
Posted by Michael Wonder on 19 Oct 2022
Oestradiol hemifumarate with norethisterone acetate and relugolix for the treatment of moderate to severe symptoms of uterine fibroids
19 October 2022 - NICE has published evidence based recommendations on the use of oestradiol hemifumarate with norethisterone acetate and ...
Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...
Posted by Michael Wonder on 19 Oct 2022
Women call for 'life-changing' medicinal cannabis oil to be added to Pharmaceutical Benefits Scheme
18 October 2022 - At 79 years old, Trish Fisher still suffers from excruciating pain from a motorbike accident in her ...
Posted by Michael Wonder on 18 Oct 2022
Department of Health and Aged Care publishes revised agenda for November 2022 PBAC meeting
18 October 2022 - Version 3 notes 9 amendments, including the withdrawal of a resubmission for a new medicine. ...
Posted by Michael Wonder on 17 Oct 2022
Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss
17 October 2022 - Quebec leads the way as the first province to reimburse Luxturna (voretigene neparvovec) for previously untreatable inherited ...
Posted by Michael Wonder on 14 Oct 2022
Outcomes from the September 2022 PBAC intracycle meeting
14 October 2022 - The recommendations made by the PBAC in September 2022 relating to the listing of medicines on ...